Leonid Dubrovsky - Concepedia

Author

Leonid Dubrovsky

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

L. Dubrovsky, L., Dubrovsky, Leonid Dubrovsky

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Eisai (United States)Icahn School of Medicine at Mount Sinai Kindai University University of California, Los Angeles

About

Leonid Dubrovsky is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.1K
2	Hepatology	5	5	776
3	Health Sciences	3	3	548
4	Cell Biology	2	2	248
5	Biomolecular Engineering	1	1	107

Leonid Dubrovsky

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Journal of Clinical Oncology	2020	1.1K
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study Masatoshi Kudo, Zhenggang Ren, Yabing Guo, The Lancet HepatologyNon-metastatic Hepatocellular CarcinomaTransarterial ChemoembolisationMedicinePharmacology	2025	161
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 Tao Dao, Dmitry Pankov, Andrew Scott, Nature Biotechnology Tumor ImmunologyCancer ImmunosurveillanceImmunologyIntracellular Oncoprotein Wt1Antigen Processing	2015	156
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. Josep M. Llovet, Masatoshi Kudo, Ann‐Lii Cheng, Journal of Clinical Oncology Tps4152 BackgroundPathologyFirst-line TreatmentPharmacotherapyPre-clinical Pharmacology	2019	109
Sequence Context Modulates the Stability of a GxxxG-mediated Transmembrane Helix–Helix Dimer Abigail K. Doura, Felix J. Kobus, Leonid Dubrovsky, Journal of Molecular Biology Proteinlipid InteractionMolecular BiologyMembrane BiologySequence ContextProtein Transport	2004	107
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment Josep M. Llovet, Arndt Vogel, David C. Madoff, CardioVascular and Interventional Radiology	2022	97
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens Aaron Y. Chang, Tao Dao, Ron S. Gejman, Journal of Clinical Investigation Tcrm AntibodiesT-regulatory CellImmunologyImmune RegulationImmunoediting	2017	92
A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). Andrew X. Zhu, Richard S. Finn, Masafumi Ikeda, Journal of Clinical Oncology PathologyPharmacotherapyImmunotherapyPre-clinical PharmacologyTranslational Medicine	2020	75
A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results Josep M. Llovet, Karen Shepard, RS Finn, Annals of Oncology HepatologyMedicinePharmacologyPathologyPhase Ib Trial	2019	67

Page 1